Correspondence: Keith V Nance Department of Pathology, Rex Hospital, 4420 Lake Boone Trail, Raleigh, NC, USA Tel +1 919 784 3063 Fax +1 919 784 3362 Email [email protected] Dear Editor Recently I communicated with the Editor regarding Drs Naryshkin and Austins’ article entitled “Limitations of widely used high-risk human papillomavirus laboratory-developed testing in cervical carcinoma ...

New commercially available Human Papillomavirus (HPV) assays need to be evaluated in a variety of cervical screening settings. Cobas HPV Test (cobas) is a real-time PCR-based assay allowing for separate detection of HPV genotypes 16 and 18 and a bulk of 12 other high-risk genotypes. The aim of the present study, Horizon, was to assess the prevalence of high-risk HPV infections in an area with a...

BACKGROUND AND METHODS We investigated the efficacy of 8 cervical cancer screening strategies relative to cytology with emphasis on immunocytochemical detection of high-risk human papillomavirus (hrHPV)-induced cell transformation (BD-ProExC) as a tool of triage following primary cytology or hrHPV testing. 3,126 women were tested with BD-SurePath liquid-based cytology, hrHPV PCR genotyping and ...

Human papillomavirus (HPV) DNA genotyping is an essential test to establish efficacy in HPV vaccine clinical trials and HPV prevalence in natural history studies. A number of HPV DNA genotyping methods have been cited in the literature, but the comparability of the outcomes from the different methods has not been well characterized. Clinically, cytology is used to establish possible HPV infecti...

The conventional Pap test is highly effective for screening of cervical cancer and its precursors but has a false negative rate due to either sampling, preparation or screening. New technologies, such as liquid-based Paps, automated screening devices and high-risk (HR) HPV testing by molecular methods, have been introduced to increase the detection of cervical disease. Two liquid-based technolo...